Loading…
Chemerin : a biomarker for cardiovascular disease in diabetic chronic kidney disease patients
Cardiovascular disease is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). The carotid intima-media thickness (CIMT) and arterial stiffness are useful markers of subclinical atherosclerosis and significantly correlate with various metabolic risk factors. Ch...
Saved in:
| Published in: | Saudi journal of kidney diseases and transplantation 2016-09, Vol.27 (5), p.977-984 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c614n-779544a0d291477d9c808f1f53a1fc45871bfaddb8858a186c936b3e2b1f90533 |
|---|---|
| cites | |
| container_end_page | 984 |
| container_issue | 5 |
| container_start_page | 977 |
| container_title | Saudi journal of kidney diseases and transplantation |
| container_volume | 27 |
| creator | al-Said, al-Sayyid Hasan Abd al-Rahman, Abd al-Naim A. Anas, Qasim A. Salamah, Farraj E. |
| description | Cardiovascular disease is the leading cause of morbidity and mortality in patients
with chronic kidney disease (CKD). The carotid intima-media thickness (CIMT) and arterial
stiffness are useful markers of subclinical atherosclerosis and significantly correlate with various
metabolic risk factors. Chemerin is one of the adipokines that may represent a link between
obesity and inflammation and may be a potential candidate playing a role in the pathogenesis of
atherosclerosis and cardiovascular complications. Therefore, we studied the relationship of
chemerin levels with atherosclerosis as measured by CIMT in diabetic CKD patients, either
predialysis or on hemodialysis (HD). In addition, we studied its correlation with other
cardiovascular risk factors such as interleukin-6 (IL-6) and insulin resistance (IR). Fifty-eight
patients were enrolled in the study; 23 patients with CKD (11 are diabetic) on conservative
treatment and 35 (18 are diabetic) on maintenance HD. Serum concentrations of chemerin and IL-
6 were determined by ELISA. All participants underwent measurements of CIMT by highresolution
ultrasonography. A stepwise increase in serum chemerin levels was found depending
on the glomerular filtration rate: 286.6 ± 10.02 ng/mL in the control group, 332.1 ± 21.54 ng/mL
in the predialysis group, and 355.7 ± 20 ng/mL in the HD group. A significant rise of serum
chemerin level was observed in diabetic CKD patients either on conservative therapy or on HD
when compared with nondiabetic CKD patients. Moreover, there was a significant difference in
serum levels of chemerin, IL-6, CIMT, serum insulin, and homeostasis model assessment of IR
(HOMA-IR) between diabetic and nondiabetic patients in both groups. Chemerin showed a
significant positive correlation with HOMA-IR, serum insulin, and C-reactive protein. In
conclusion, serum chemerin level was found to be an independent predictive marker of the
presence of atherosclerosis in patients with CKD either on conservative treatment or on HD. |
| doi_str_mv | 10.4103/1319-2442.190867 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_df6e6532efcb48359b593d5638a1e7c8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A464228086</galeid><doaj_id>oai_doaj_org_article_df6e6532efcb48359b593d5638a1e7c8</doaj_id><sourcerecordid>A464228086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c614n-779544a0d291477d9c808f1f53a1fc45871bfaddb8858a186c936b3e2b1f90533</originalsourceid><addsrcrecordid>eNptks1v0zAYhyMEYmVw5wKKhIS4pPgzdnYbFR-TJnGBI7Ic-_XqNo2LnVDtv8chW1kRysGS87yP_bN-RfESoyXDiL7HFDcVYYwscYNkLR4VC0IJqqik8nGxOP4-K56ltEGI86aunxZnRAhOEBKL4sdqDTuIvi8vSl22Pux03EIsXYil0dH68EsnM3Y6ltYn0AnKzFqvWxi8Kc06hj6vW297uD0iez146If0vHjidJfgxd16Xnz_9PHb6kt1_fXz1eryujI1Zn0lRMMZ08iSBjMhbGMkkg47TjV2hnEpcOu0ta2UXGosa9PQuqVAWuwaxCk9L65mrw16o_bR5xS3Kmiv_myEeKN0zPftQFlXQ80pAWdaJilvWt5Qy2uaxSCMzK53s2sfw88R0qB2PhnoOt1DGJPCeYhxkl84o2_-QTdhjH1OOlE5i0SU_KVudD7f9y4MUZtJqi5ZzQjJYetMLf9D5c_CzpvQg_N5_2Tg7YOBNehuWKfQjYMPfToF0QyaGFKK4I4PhJGaaqSmnqipJ2quUR55fRdsbHdgjwP3vcnAhxk4hG6AmLbdeICoMrvtw-FEXD0Qq0YIdd-4LHk1SyDLwenjMQILTBD9Dbj53Rk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1839148032</pqid></control><display><type>article</type><title>Chemerin : a biomarker for cardiovascular disease in diabetic chronic kidney disease patients</title><source>Medknow Open Access Journals</source><source>Publicly Available Content Database</source><creator>al-Said, al-Sayyid Hasan ; Abd al-Rahman, Abd al-Naim A. ; Anas, Qasim A. ; Salamah, Farraj E.</creator><creatorcontrib>al-Said, al-Sayyid Hasan ; Abd al-Rahman, Abd al-Naim A. ; Anas, Qasim A. ; Salamah, Farraj E.</creatorcontrib><description>Cardiovascular disease is the leading cause of morbidity and mortality in patients
with chronic kidney disease (CKD). The carotid intima-media thickness (CIMT) and arterial
stiffness are useful markers of subclinical atherosclerosis and significantly correlate with various
metabolic risk factors. Chemerin is one of the adipokines that may represent a link between
obesity and inflammation and may be a potential candidate playing a role in the pathogenesis of
atherosclerosis and cardiovascular complications. Therefore, we studied the relationship of
chemerin levels with atherosclerosis as measured by CIMT in diabetic CKD patients, either
predialysis or on hemodialysis (HD). In addition, we studied its correlation with other
cardiovascular risk factors such as interleukin-6 (IL-6) and insulin resistance (IR). Fifty-eight
patients were enrolled in the study; 23 patients with CKD (11 are diabetic) on conservative
treatment and 35 (18 are diabetic) on maintenance HD. Serum concentrations of chemerin and IL-
6 were determined by ELISA. All participants underwent measurements of CIMT by highresolution
ultrasonography. A stepwise increase in serum chemerin levels was found depending
on the glomerular filtration rate: 286.6 ± 10.02 ng/mL in the control group, 332.1 ± 21.54 ng/mL
in the predialysis group, and 355.7 ± 20 ng/mL in the HD group. A significant rise of serum
chemerin level was observed in diabetic CKD patients either on conservative therapy or on HD
when compared with nondiabetic CKD patients. Moreover, there was a significant difference in
serum levels of chemerin, IL-6, CIMT, serum insulin, and homeostasis model assessment of IR
(HOMA-IR) between diabetic and nondiabetic patients in both groups. Chemerin showed a
significant positive correlation with HOMA-IR, serum insulin, and C-reactive protein. In
conclusion, serum chemerin level was found to be an independent predictive marker of the
presence of atherosclerosis in patients with CKD either on conservative treatment or on HD.</description><identifier>ISSN: 1319-2442</identifier><identifier>EISSN: 2320-3838</identifier><identifier>DOI: 10.4103/1319-2442.190867</identifier><identifier>PMID: 27752007</identifier><language>eng</language><publisher>Riyadh, Saudi Arabia: Saudi Center for Organ Transplantation</publisher><subject>Atherosclerosis ; Biological markers ; Biomarkers ; Cardiovascular disease ; Cardiovascular Diseases ; Carotid arteries ; Carotid Intima-Media Thickness ; Chemokines ; Cholesterol ; Complications and side effects ; Cytokines ; Development and progression ; Diabetes ; Diabetic nephropathies ; Enzymes ; Gene expression ; Genetic aspects ; Health aspects ; Humans ; Identification and classification ; Immunoassay ; Insulin ; Insulin resistance ; Kidney diseases ; Metabolism ; Mortality ; Pathogenesis ; Properties ; Proteins ; Renal Insufficiency, Chronic ; Risk Factors ; Studies ; Substance abuse treatment ; Ultrasonic imaging ; الأمراض ; الجهاز القلبي الوعائي ; الفشل الكلوي ; المرضى ; المستقبلات ; الواسمات الحيوية ; تريتينوين ; مرضى السكري</subject><ispartof>Saudi journal of kidney diseases and transplantation, 2016-09, Vol.27 (5), p.977-984</ispartof><rights>COPYRIGHT 2016 Medknow Publications and Media Pvt. Ltd.</rights><rights>Copyright Medknow Publications & Media Pvt Ltd Sep-Oct 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c614n-779544a0d291477d9c808f1f53a1fc45871bfaddb8858a186c936b3e2b1f90533</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1839148032?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,25732,27903,27904,36991,36992,44569</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27752007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>al-Said, al-Sayyid Hasan</creatorcontrib><creatorcontrib>Abd al-Rahman, Abd al-Naim A.</creatorcontrib><creatorcontrib>Anas, Qasim A.</creatorcontrib><creatorcontrib>Salamah, Farraj E.</creatorcontrib><title>Chemerin : a biomarker for cardiovascular disease in diabetic chronic kidney disease patients</title><title>Saudi journal of kidney diseases and transplantation</title><addtitle>Saudi J Kidney Dis Transpl</addtitle><description>Cardiovascular disease is the leading cause of morbidity and mortality in patients
with chronic kidney disease (CKD). The carotid intima-media thickness (CIMT) and arterial
stiffness are useful markers of subclinical atherosclerosis and significantly correlate with various
metabolic risk factors. Chemerin is one of the adipokines that may represent a link between
obesity and inflammation and may be a potential candidate playing a role in the pathogenesis of
atherosclerosis and cardiovascular complications. Therefore, we studied the relationship of
chemerin levels with atherosclerosis as measured by CIMT in diabetic CKD patients, either
predialysis or on hemodialysis (HD). In addition, we studied its correlation with other
cardiovascular risk factors such as interleukin-6 (IL-6) and insulin resistance (IR). Fifty-eight
patients were enrolled in the study; 23 patients with CKD (11 are diabetic) on conservative
treatment and 35 (18 are diabetic) on maintenance HD. Serum concentrations of chemerin and IL-
6 were determined by ELISA. All participants underwent measurements of CIMT by highresolution
ultrasonography. A stepwise increase in serum chemerin levels was found depending
on the glomerular filtration rate: 286.6 ± 10.02 ng/mL in the control group, 332.1 ± 21.54 ng/mL
in the predialysis group, and 355.7 ± 20 ng/mL in the HD group. A significant rise of serum
chemerin level was observed in diabetic CKD patients either on conservative therapy or on HD
when compared with nondiabetic CKD patients. Moreover, there was a significant difference in
serum levels of chemerin, IL-6, CIMT, serum insulin, and homeostasis model assessment of IR
(HOMA-IR) between diabetic and nondiabetic patients in both groups. Chemerin showed a
significant positive correlation with HOMA-IR, serum insulin, and C-reactive protein. In
conclusion, serum chemerin level was found to be an independent predictive marker of the
presence of atherosclerosis in patients with CKD either on conservative treatment or on HD.</description><subject>Atherosclerosis</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases</subject><subject>Carotid arteries</subject><subject>Carotid Intima-Media Thickness</subject><subject>Chemokines</subject><subject>Cholesterol</subject><subject>Complications and side effects</subject><subject>Cytokines</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Diabetic nephropathies</subject><subject>Enzymes</subject><subject>Gene expression</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Identification and classification</subject><subject>Immunoassay</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Kidney diseases</subject><subject>Metabolism</subject><subject>Mortality</subject><subject>Pathogenesis</subject><subject>Properties</subject><subject>Proteins</subject><subject>Renal Insufficiency, Chronic</subject><subject>Risk Factors</subject><subject>Studies</subject><subject>Substance abuse treatment</subject><subject>Ultrasonic imaging</subject><subject>الأمراض</subject><subject>الجهاز القلبي الوعائي</subject><subject>الفشل الكلوي</subject><subject>المرضى</subject><subject>المستقبلات</subject><subject>الواسمات الحيوية</subject><subject>تريتينوين</subject><subject>مرضى السكري</subject><issn>1319-2442</issn><issn>2320-3838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks1v0zAYhyMEYmVw5wKKhIS4pPgzdnYbFR-TJnGBI7Ic-_XqNo2LnVDtv8chW1kRysGS87yP_bN-RfESoyXDiL7HFDcVYYwscYNkLR4VC0IJqqik8nGxOP4-K56ltEGI86aunxZnRAhOEBKL4sdqDTuIvi8vSl22Pux03EIsXYil0dH68EsnM3Y6ltYn0AnKzFqvWxi8Kc06hj6vW297uD0iez146If0vHjidJfgxd16Xnz_9PHb6kt1_fXz1eryujI1Zn0lRMMZ08iSBjMhbGMkkg47TjV2hnEpcOu0ta2UXGosa9PQuqVAWuwaxCk9L65mrw16o_bR5xS3Kmiv_myEeKN0zPftQFlXQ80pAWdaJilvWt5Qy2uaxSCMzK53s2sfw88R0qB2PhnoOt1DGJPCeYhxkl84o2_-QTdhjH1OOlE5i0SU_KVudD7f9y4MUZtJqi5ZzQjJYetMLf9D5c_CzpvQg_N5_2Tg7YOBNehuWKfQjYMPfToF0QyaGFKK4I4PhJGaaqSmnqipJ2quUR55fRdsbHdgjwP3vcnAhxk4hG6AmLbdeICoMrvtw-FEXD0Qq0YIdd-4LHk1SyDLwenjMQILTBD9Dbj53Rk</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>al-Said, al-Sayyid Hasan</creator><creator>Abd al-Rahman, Abd al-Naim A.</creator><creator>Anas, Qasim A.</creator><creator>Salamah, Farraj E.</creator><general>Saudi Center for Organ Transplantation</general><general>Wolters Kluwer - Medknow Publications</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications & Media Pvt. Ltd</general><general>Wolters Kluwer Medknow Publications</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>20160901</creationdate><title>Chemerin : a biomarker for cardiovascular disease in diabetic chronic kidney disease patients</title><author>al-Said, al-Sayyid Hasan ; Abd al-Rahman, Abd al-Naim A. ; Anas, Qasim A. ; Salamah, Farraj E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c614n-779544a0d291477d9c808f1f53a1fc45871bfaddb8858a186c936b3e2b1f90533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Atherosclerosis</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases</topic><topic>Carotid arteries</topic><topic>Carotid Intima-Media Thickness</topic><topic>Chemokines</topic><topic>Cholesterol</topic><topic>Complications and side effects</topic><topic>Cytokines</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Diabetic nephropathies</topic><topic>Enzymes</topic><topic>Gene expression</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Identification and classification</topic><topic>Immunoassay</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Kidney diseases</topic><topic>Metabolism</topic><topic>Mortality</topic><topic>Pathogenesis</topic><topic>Properties</topic><topic>Proteins</topic><topic>Renal Insufficiency, Chronic</topic><topic>Risk Factors</topic><topic>Studies</topic><topic>Substance abuse treatment</topic><topic>Ultrasonic imaging</topic><topic>الأمراض</topic><topic>الجهاز القلبي الوعائي</topic><topic>الفشل الكلوي</topic><topic>المرضى</topic><topic>المستقبلات</topic><topic>الواسمات الحيوية</topic><topic>تريتينوين</topic><topic>مرضى السكري</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>al-Said, al-Sayyid Hasan</creatorcontrib><creatorcontrib>Abd al-Rahman, Abd al-Naim A.</creatorcontrib><creatorcontrib>Anas, Qasim A.</creatorcontrib><creatorcontrib>Salamah, Farraj E.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Saudi journal of kidney diseases and transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>al-Said, al-Sayyid Hasan</au><au>Abd al-Rahman, Abd al-Naim A.</au><au>Anas, Qasim A.</au><au>Salamah, Farraj E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemerin : a biomarker for cardiovascular disease in diabetic chronic kidney disease patients</atitle><jtitle>Saudi journal of kidney diseases and transplantation</jtitle><addtitle>Saudi J Kidney Dis Transpl</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>27</volume><issue>5</issue><spage>977</spage><epage>984</epage><pages>977-984</pages><issn>1319-2442</issn><eissn>2320-3838</eissn><abstract>Cardiovascular disease is the leading cause of morbidity and mortality in patients
with chronic kidney disease (CKD). The carotid intima-media thickness (CIMT) and arterial
stiffness are useful markers of subclinical atherosclerosis and significantly correlate with various
metabolic risk factors. Chemerin is one of the adipokines that may represent a link between
obesity and inflammation and may be a potential candidate playing a role in the pathogenesis of
atherosclerosis and cardiovascular complications. Therefore, we studied the relationship of
chemerin levels with atherosclerosis as measured by CIMT in diabetic CKD patients, either
predialysis or on hemodialysis (HD). In addition, we studied its correlation with other
cardiovascular risk factors such as interleukin-6 (IL-6) and insulin resistance (IR). Fifty-eight
patients were enrolled in the study; 23 patients with CKD (11 are diabetic) on conservative
treatment and 35 (18 are diabetic) on maintenance HD. Serum concentrations of chemerin and IL-
6 were determined by ELISA. All participants underwent measurements of CIMT by highresolution
ultrasonography. A stepwise increase in serum chemerin levels was found depending
on the glomerular filtration rate: 286.6 ± 10.02 ng/mL in the control group, 332.1 ± 21.54 ng/mL
in the predialysis group, and 355.7 ± 20 ng/mL in the HD group. A significant rise of serum
chemerin level was observed in diabetic CKD patients either on conservative therapy or on HD
when compared with nondiabetic CKD patients. Moreover, there was a significant difference in
serum levels of chemerin, IL-6, CIMT, serum insulin, and homeostasis model assessment of IR
(HOMA-IR) between diabetic and nondiabetic patients in both groups. Chemerin showed a
significant positive correlation with HOMA-IR, serum insulin, and C-reactive protein. In
conclusion, serum chemerin level was found to be an independent predictive marker of the
presence of atherosclerosis in patients with CKD either on conservative treatment or on HD.</abstract><cop>Riyadh, Saudi Arabia</cop><pub>Saudi Center for Organ Transplantation</pub><pmid>27752007</pmid><doi>10.4103/1319-2442.190867</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1319-2442 |
| ispartof | Saudi journal of kidney diseases and transplantation, 2016-09, Vol.27 (5), p.977-984 |
| issn | 1319-2442 2320-3838 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_df6e6532efcb48359b593d5638a1e7c8 |
| source | Medknow Open Access Journals; Publicly Available Content Database |
| subjects | Atherosclerosis Biological markers Biomarkers Cardiovascular disease Cardiovascular Diseases Carotid arteries Carotid Intima-Media Thickness Chemokines Cholesterol Complications and side effects Cytokines Development and progression Diabetes Diabetic nephropathies Enzymes Gene expression Genetic aspects Health aspects Humans Identification and classification Immunoassay Insulin Insulin resistance Kidney diseases Metabolism Mortality Pathogenesis Properties Proteins Renal Insufficiency, Chronic Risk Factors Studies Substance abuse treatment Ultrasonic imaging الأمراض الجهاز القلبي الوعائي الفشل الكلوي المرضى المستقبلات الواسمات الحيوية تريتينوين مرضى السكري |
| title | Chemerin : a biomarker for cardiovascular disease in diabetic chronic kidney disease patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T23%3A16%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemerin%20:%20a%20biomarker%20for%20cardiovascular%20disease%20in%20diabetic%20chronic%20kidney%20disease%20patients&rft.jtitle=Saudi%20journal%20of%20kidney%20diseases%20and%20transplantation&rft.au=al-Said,%20al-Sayyid%20Hasan&rft.date=2016-09-01&rft.volume=27&rft.issue=5&rft.spage=977&rft.epage=984&rft.pages=977-984&rft.issn=1319-2442&rft.eissn=2320-3838&rft_id=info:doi/10.4103/1319-2442.190867&rft_dat=%3Cgale_doaj_%3EA464228086%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c614n-779544a0d291477d9c808f1f53a1fc45871bfaddb8858a186c936b3e2b1f90533%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1839148032&rft_id=info:pmid/27752007&rft_galeid=A464228086&rfr_iscdi=true |